Gastric ulcer healing after treatment of endoscopic submucosal dissection in Japanese: comparison of $H_2$ receptor antagonist and proton pump inhibitor administration

Nozomi Takeuchi, Eiji Umegaki,* Toshihisa Takeuchi, Mitsuyuki Murano, Yukiko Yoda, Satoshi Tokioka and Kazuhide Higuchi

Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki-shi, Osaka 569-8686, Japan

(Received 13 February, 2011; Accepted 16 March, 2011; Published online 29 April, 2011)

Endoscopic submucosal dissection has made it possible to resect large lesions during a single operation. The present study was undertaken to compare the time taken for recovery from artificial ulcers after endoscopic submucosal dissection between an $H_2$ Receptor Antagonist treatment group and a Proton Pump Inhibitor treatment group, focusing on analysis of the time course of reduction rate in ulcer area. The powerful acid suppression by Proton Pump Inhibitor may not be needed to treat Japanese post-endoscopic submucosal dissection ulcer which usually develops after early gastric carcinoma in the mucosa of low acid secretory capacity. The study involved 60 patients with 69 artificial ulcers following endoscopic submucosal dissection for the treatment of tumors remaining in the gastric mucosa. Of all lesions, 36 were allocated to the $H_2$ Receptor Antagonist group and 33 to the Proton Pump Inhibitor group. Patients in both groups underwent endoscopy at 4 and 8 weeks after the start of administration. There were no significant differences between two groups and ulcer healing rates were similar in the two groups. The efficacy of $H_2$ Receptor Antagonists in curing this type of ulcer can thus be expected to be comparable to that of Proton Pump Inhibitors.

Key Words: endoscopic submucosal dissection, $H_2$ receptor antagonist, proton pump inhibitor, gastric ulcer healing

Endoscopic therapy for early gastric carcinoma was initiated in the 1960s and various technologies were developed. Since the strip biopsy method developed by Tada et al. (1) and the ERHSE (Endoscopic Resection with local injection of Hypertonic Saline Epinephrine solution) method developed by Hirao et al. (2) became available in the 1980s, endoscopic mucosal resection (EMR) for endoscopic therapy has come into widespread use. Various techniques have also become well-developed but most have focused on treatment of intra-mucosal lesions of 2 cm or less and therefore post-EMR ulcers have, like peptic ulcers, been treated with $H_2$ receptor antagonists (H:RA) or proton pump inhibitors (PPI). (3,4) The insulated tip electrosurgical (IT)-knife (5) developed in 1988 and the approach of Ono et al. (6) in 1999 allowed dissection of larger lesions exceeding 2 cm; this treatment approach was termed endoscopic submucosal dissection (ESD). ESD enables larger specimens to be obtained, resulting in a complete resection rate of more than 90% compared with conventional EMR methods.

Post-ESD ulcers have been treated with H:RA or PPI like other post-EMR ulcers. The size of an ulcer artificially induced by endoscopic therapies including ESD is generally shallower than a common peptic ulcer. A meta-analysis found that peptic ulcers are potentially curable earlier with PPIs than H:RAs due to the stronger inhibitory action on gastric acid secretion. (7) However, there is no well-documented report examining whether treatment of post-ESD ulcers and that of common peptic ulcers should be same or not.

Most early gastric carcinomas, as indications for endoscopic therapy, are classified as well-differentiated with severe atrophy in the background mucosa of the stomach and an inferred decrease in acid secretory capacity. In addition, it is reported that 70 to 80% of Japanese were infected with Helicobacter pylori (HP) and that the acid secretion potential was lower in Japanese people than in Western populations. (8) Due to the change of dietary habits to Western-style, the acid secretion in Japanese tends to increase, but it is still lower than in Western populations. (9) Therefore, the powerful acid suppression by PPI may not be needed to treat Japanese post-ESD ulcer which usually develops after early gastric carcinoma in the mucosa of low acid secretory capacity.

For ulcer healing after EMR, Yamaguchi et al. (10) evaluated the effectiveness of H:RA and PPI, and concluded that the healing results were similar for the two drugs. However, whether or not the treatment for peptic ulcer is also effective for post-ESD ulcer, and which drugs are suitable for post-ESD ulcers with larger area than post-EMR ulcers, have not yet been examined.

Therefore, we compared the rate of decrease in ulcer size over time in patients with post-ESD ulcers treated with H:RA or PPI to establish a regimen for ESD-induced ulcers assumed to have a similar depth of ulceration.

Subjects and Methods

Subjects. We conducted ESD for 65 patients with 74 gastric intra-mucosal tumors between January and June 2009 at the Osaka Medical College Hospital, Japan. We excluded patients with multi-organ complications and included 60 patients with 69 gastric tumors (51 early gastric carcinomas, 18 gastric adenomas) after giving written informed consent in this study. Subjects were randomly allocated into two groups (30 in each group) using the envelop method (Fig. 1).

ESD procedure. The ESD procedure was performed with the approach of Ono et al. (6) and the actual steps are shown in Fig. 2. VIO300D (ERBE, Tubingen, Germany) was used as a high-frequency generator. A needle knife (KD-IL, Olympus Medical Systems Co. Ltd., Tokyo, Japan) (10) as the marking-tip device was
N. Takeuchi et al.

used with a coagulation wave (Soft Coag 60W Effect 7) to mark dots approximately 5 mm outside the margin of the targeted lesion. Then, the mucosa around the lesion was adequately inflated by locally injecting 0.05% epinephrine dissolved in saline into the area between the muscularis propria and the mucosa. The lesion was pre-cut using the needle knife with the cut wave (Endo Cut I Effect 2 Duration 3 Interval 3) and incised circumferentially using an IT-knife 2

Fig. 2. The ESD procedure and hemostasis. a: A IIa gastric tumor with the long axis of 10 mm at anterior pylorus. b: The lesion dyed with indigocar- mine. c: Marking outer margin of the lesion by a coagulation wave. d: Inflation of the mucosa around the lesion by local injection of solution. e: The lesion after circumferential incision. f: Dissection of the lesion by IT-knife 2. g: The lesion during dissection. h: An ulcer floor formed immediately after ESD. i: Hemostasis of vessels in the ulcer floor.

3). The submucosal layer under the lesion was dissected using the same IT knife 2, usually with the coagulation wave (Swift Coag Effect 2, 60–70W), but occasionally with the cut wave (Endo Cut Q Effect 2 Duration 4 Interval 3) for the hard-to-dissect fibrous submucosal layer. The IT-knife 2 with the coagulation wave (Swift Coag Effect 3, 60–80W) was used to stop oozing blood during the procedure. In case of inadequate hemostasis, a soft coagulation wave (Soft Coag Effect 6, 80W) was applied to the bleeding site pinpointed and clamped with hemostatic forceps (FD-410LR,
Olympus Medical Systems Co. Ltd.) to stop bleeding. The hemostatic forceps were also used for projectile bleeding; in the event of poor heat transfer of the soft coagulation wave to vessels, another hemostatic forceps with a larger contact area (Radial Jow 3 HOT Boston Scientific, Marlborough, Natick Massachusetts) and another setting for the higher-frequency coagulation wave ( Forced Effect 2, 40W) with a coagulation output of approximately 1–2 s were used to stop the bleeding.

After dissection of the target lesion, all vessels in the floor of the ulcer were carefully treated using hemostatic forceps and with the coagulation wave (Soft Coag 80W Effect 6) for prophylaxis against post-operative hemorrhage.

Bleeding was defined as hematemesis or melena that required the endoscopic hemostasis and decreased the hemoglobin count by more than 2 g/dl, occurring from the time of treatment until cure of ESD-induced ulcer (Fig. 2).

**Study protocol design (post-ESD treatment).** Patients were not fed for 2 days after ESD procedures and received roxatidine acetate hydrochloride, an intravenous H$_2$RA given at a dosage of 150 mg/day during the fasting period. Then, both patient groups received an anti-ulcer drug orally for 8 weeks; the H$_2$RA group received roxatidine acetate 150 mg/day and the PPI group received rabeprazole 10 mg/day. Patients in both groups underwent upper gastrointestinal endoscopy at 4 and 8 weeks after the start of administration.

**Measurement of ulcer size.** The ESD-induced ulcer size was assessed by area; long and short axes (mm) of an assumed ellipse were measured using an endoscope and measuring equipment, and the ulcer size was calculated.

**Results**

**Patient characteristics.** The H$_2$RA group (30 patients) and the PPI group (30 patients) were studied. The H$_2$RA group consisted of 20 males and 10 females with a mean age of 68.7 ± 9.3 years, range 49 to 85, whereas the PPI group consisted of 21 males and 9 females with a mean age of 67.4 ± 7.8 years, range 47 to 80. HP IgG antibody levels in blood were measured (using ELISA kit: HM-CAP, Kyowa Medex, Tokyo, Japan) and the level of 1.8 U/ml or above was considered to be HP positive. The HP infection rate was 76.7% in the H$_2$RA group and 80.0% in the PPI group. The H$_2$RA group patients had ulcers (36 lesions) in the body (14 lesions), angulus (10) and antrum (12) of the stomach. The PPI group patients had ulcers (33 lesions) in the body (12 lesions), angulus (9) and antrum (12) of the stomach. There were no significant differences in extraneous factors between the two groups (Table 1).

**Ulcer size after ESD.** Ulcer sizes after ESD (baseline value) were 519.2 ± 436.7 in the H$_2$RA group (36 lesions) and 652.2 ± 514.4 in the PPI group (33 lesions) and there was no significant difference between the two groups (Table 2).

**The rate of decrease in ulcer size.** The rates of decrease in ulcer size were 92.9 ± 9.1% and 99.8 ± 0.7% at Week 4 and Week 8, respectively, in the H$_2$RA group, and 89.0 ± 20.1% and 97.7 ± 1.1% in the PPI group, respectively. There were no significant differences between the two groups (Table 3).

**Ulcers less than 400 mm$^2$.** The mean size of 19 ulcers which were less than 400 mm$^2$ immediately after ESD was 263.6 ± 73.3 mm$^2$ in the H$_2$RA group and the rate of decrease in size was 96.1 ± 6.0% at Week 4 and 100% at Week 8. The mean size of 13 ulcers was 276.4 ± 51.6 mm$^2$ in the PPI group and the rate of decrease in size was 94.2 ± 5.1% at Week 4 and 99.9 ± 0.2% at Week 8. There were no significant differences between the two groups (Table 4).

**Ulcers of at least 400 mm$^2$.** The mean size of 17 ulcers exceeding 400 mm$^2$ was 804.8 ± 496.8 mm$^2$ in the H$_2$RA group and the rate of decrease in size was 89.3 ± 10.7% at Week 4 and 99.7 ± 1.0% at Week 8. The mean size of 20 large ulcers was 896.5 ± 533.4 mm$^2$ in the PPI group and the rate of decrease in size was 85.6 ± 25.2% at Week 4 and 99.5 ± 1.4% at Week 8. There were no significant differences between the two groups (Table 5).

**Post-ESD complications.** There were no patients with post-ESD bleeding in either group, from the time of treatment until cure of ESD-induced ulcer.
Fig. 5. A case treated with H2RA (Roxatidine). a: IIa early gastric cancer at the lesser curvature of gastric angle. b: The lesion was dyed with indigo-carmine. c: Immediately after ESD, an ulcer floor was formed. d: Two days after ESD, there was white moss in the ulcer floor. e: Four weeks after ESD, the ulcer floor shrunk and was surrounded by regenerating epithelium. f: Eight weeks after ESD, the ulcer floor disappeared and turned into a scar.

Table 1. Patient characteristics of the treatment groups (H2RA and PPI)

| Variables | H2RA | PPI |
|-----------|------|-----|
| Patients (n) | 30 | 30 |
| Male | 20 | 21 |
| Female | 10 | 9 |
| Age: mean ± SD | 68.7 ± 9.3 | 67.4 ± 7.8 |
| (Range) | (49–85) | (47–80) |
| H. pylori positive (%) | (76.7%) | (80.0%) |
| Lesions (n) | 36 | 33 |
| Site of lesions | | |
| Body | 14 | 12 |
| Angle | 10 | 9 |
| Antrum | 12 | 12 |
| Area of ulcer at 0W (mm2) | 519.2 ± 436.7 | 652.2 ± 514.4 |

The patient characteristics were similar in both groups, and no significant differences were observed. H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.

Table 2. Ulcer size at baseline (mm2)

|        | 0 W | 95% CI           |
|--------|-----|------------------|
| H2RA (n = 36) | 519.2 ± 436.7 | (376.5–661.8) |
| PPI (n = 33) | 652.2 ± 514.4 | (476.7–827.7) |

Ulcer sizes after ESD (baseline value) were 519.2 ± 436.7 in the H2RA group (36 lesions) and 652.2 ± 514.4 in the PPI group (33 lesions) and there was no significant difference between the two groups. ESD, endoscopic submucosal dissection; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.

Table 3. The rate of decrease in ulcer size (all ulcers)

|        | Week 4 | Week 8 |
|--------|--------|--------|
| H2RA (n = 36) | 92.9 ± 9.1% | 99.8 ± 0.7% |
| PPI (n = 33) | 89.0 ± 20.1% | 97.7 ± 1.1% |

The rates of decrease in ulcer size were 92.9 ± 9.1% and 99.8 ± 0.7% at Week 4 and Week 8, respectively, in the H2RA group, and 89.0 ± 20.1% and 97.7 ± 1.1% in the PPI group, respectively. There were no significant differences between the two groups. H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.

Table 4. The rate of decrease in ulcer size (ulcers less than 400 mm2)

|        | Week 4 | Week 8 |
|--------|--------|--------|
| H2RA (n = 19) | 96.1 ± 6.0% | 100% |
| PPI (n = 13) | 94.2 ± 5.1% | 99.9 ± 0.1% |

The mean size of 19 ulcers which were less than 400 mm2 immediately after ESD was 263.6 ± 73.3 mm2 in the H2RA group and the rate of decrease in size was 96.1 ± 6.0% at Week 4 and 100% at Week 8. The mean size of 13 ulcers was 276.4 ± 51.6 mm2 in the PPI group and the rate of decrease in size was 94.2 ± 5.1% at Week 4 and 99.9 ± 0.2% at Week 8. There were no significant differences between the two groups. ESD, endoscopic submucosal dissection; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor.
## Discussion

ESD is becoming the standard treatment for gastric intramucosal tumors and an effective cure for post-ESD ulcers is anticipated to be an important future issue. Eriksson et al.\(^{(12)}\) compared H:\textregistered RA (ranitidine) and PPI (omeprazole) in 743 patients with gastric ulcers and the outcome as the rates of ulcer healing at Week 4 and Week 8. The results of the meta-analysis showed that the PPI group was superior in ulcer healing rate by 9.9\% (95\% CI, 3.0–16.8) (\(p = 0.005\)) at Week 4 and 6.7\% (95\% CI, 1.2–12.2) at Week 8 (\(p = 0.02\)). Another meta-analysis by Tunis et al.\(^{(13)}\) in 1527 patients involved in 13 studies showed that the rate of ulcer healing was significantly higher in the PPI group with better outcomes at both Week 4 (risk ratio = 1.33, 95\% CI, 1.19–1.49) and Week 8 (risk ratio = 1.12, 95\% CI, 1.06–1.19) than in the H:\textregistered RA group. The depth of these peptic ulcers was varied, ranging from erosion of level mucosa to ulceration beyond the muscularis propria, whereas the depth of ESD-induced ulcers was 89.6 ± 533.4 mm\(^2\) in the PPI group and the rate of decrease in size was 85.6 ± 25.2\% at Week 4 and 99.5 ± 1.4\% at Week 8. There were no significant differences between the two groups. H:\textregistered RA, H:\textregistered receptor antagonist; PPI, proton pump inhibitor.

Yamaguchi et al.\(^{(3)}\) evaluated the bleeding rate after EMR and the effects on the healing of post-EMR ulcers of in 57 patients who were randomly assigned to H:\textregistered RA or PPI. Neither the bleeding rates (H:\textregistered RA 18\% versus PPI 14\%) nor the size of post-EMR ulcers at 1, 30, 60 days were significantly different between the two groups.

Regarding PPI treatment duration, Lee et al.\(^{(14)}\) assigned patients to treatment with PPI for 7 days (\(n = 26\)) or 28 days (\(n = 34\)) after EMR. At 4 weeks after EMR, there were no significant differences between the two groups in terms of ulcer reduction ratio or stage.

There are neither well-documented reports examining whether treatment for post-ESD ulcers and peptic ulcers produce similar outcomes nor those evaluating whether healing of post-ESD ulcers is different from post-EMR ulcers. Therefore, we compared the effects of H:\textregistered RA and PPI on ulcer healing in patients with ESD-induced ulcers. We also classified ESD-induced ulcers into 2 groups of less than 400 mm\(^2\) and at least 400 mm\(^2\) and compared ulcer healing by size.

We compared the rate of decrease in ulcer size at 4 and 8 weeks after treatment initiation. There were no significant differences between the H:\textregistered RA and PPI groups and ulcer healing rates were similar in the two groups. Post-ESD ulcer sizes were examined after stratifying ulcers into two ulcer size groups, less than 400 mm\(^2\) and at least 400 mm\(^2\); baseline, and the analysis indicated no significant difference in the rate of decrease in ulcer size between the two groups at 4 and 8 weeks after the start of treatment. Furthermore, most of the patients in both groups showed cure at Week 8.

Kim et al.\(^{(15)}\) reported that the safety and efficacy profiles of PPI and a newly developed acid-pump antagonist are similar for the treatment of ESD-induced ulcers. Kakushima et al.\(^{(16)}\) indicated that even larger post-ESD ulcers are potentially curable with PPI treatment in 8 weeks. On the other hand, this study demonstrated roxatidine acetate hydrochloride, a H:\textregistered RA, to also be as effective for post-ESD ulcers as PPIs (Fig. 5).

There are some reports\(^{(17,18)}\) that the combination therapy of PPI plus rebamipide, a mucosal-protective agent, promoted post-ESD ulcers. In this study, we compared the safety and efficacy profiles of H:\textregistered RA and PPI. Roxatidine acetate hydrochloride, H:\textregistered RA has an acid secretion inhibitory effect and a gastric mucus-increasing effect.\(^{(17,18)}\) Thus, roxatidine was considered to have favorable effects due to its pharmacological properties on healing of well-differentiated gastric carcinoma in this study; severe atrophy of the background mucosa and a possible decrease in gastric acid secretory capacity, and even decreases in gastric mucus protective factors, may all be contributory.

Bleeding is among the post-endoscopic therapy complications. Conventional EMR procedures dissecting relatively small carcinomas in a short time were considered to be less affected by electrocoagulation such that there would be no difference in post-EMR bleeding between the H:\textregistered RA and the PPI treatment groups.\(^{(3)}\) In contrast, ESD procedures using electrocautery applying an electric current to the target lesion may result in severe damage to the vessels, submucosal layer and the muscular layer on the floor of the ulcer. The incidence of postoperative bleeding was 3 to 5\% with ESD procedures, higher than with EMR procedures. Isomoto et al.\(^{(19)}\) reviewed that bleeding during ESD can be managed with coagulation forceps, and postoperative bleeding may be reduced with routine use of the PPIs. In addition, Uedo et al.\(^{(20)}\) suggested, from the perspective of prophylaxis against bleeding, that PPIs might inhibit postoperative bleeding significantly better than H:\textregistered RAs.

Specifically, since post-ESD bleeding was observed in 3.3\% of patients with tumors measuring lesser than 2 cm in diameter and 31.6\% of patients with tumors measuring 2 cm or more in diameter; they reported that the tumor size was one of the significant risk factors for post-ESD bleeding. We followed the procedures reported by Uedo et al.\(^{(20)}\) to treat any visible vessels and adherent clots in the floor of the postoperative ulcer with hot biopsy forceps in the soft coagulation mode at 80-W current. Insufficient hemostasis was treated carefully with bigger hemostatic forceps (Radial Jow 3 HOT Boston Scientific, Marlborough, Natick, Massachusetts) or with a coagulation wave at a higher-power setting ( Forced Effect 2, 40W).

Consequently, no post-ESD bleeding was observed in 69 lesions of patients receiving either H:\textregistered RA or PPI treatment in this study and the percent decrease of the ulcer size was at least 90\% in both groups at 8 weeks; there was no significant difference. Therefore, prophylactic hemostasis was considered to be useful to prevent post-ESD bleeding.

Takizawa et al.\(^{(21)}\) also indicated that prophylactic coagulation of exposed blood vessels in the ulcer floor is essential for prevention of bleeding.

Kawano et al.\(^{(22)}\) evaluated the possibility of reducing the dose of PPI for the treatment of ESD-induced ulcers and concluded that a reduced dose of PPI after 1 week of ESD was equivalent in treatment performance to the standard dose and cheaper. However, roxatidine acetate hydrochloride was considered to be a cost-effective drug due to its lower price than a reduced dose of PPIs.

Meanwhile, even though PPIs are useful for the treatment of peptic ulcers, interaction with clopidogrel used after coronary artery stenting is currently acknowledged as a problem. Both clopidogrel and PPIs are known to be metabolized by CYP2C19, therefore, PPIs may decrease the level of active metabolite of clopidogrel and attenuate the anti-platelet effect of clopidogrel. Therefore, PPIs are known to be metabolized by CYP2C19, which may be contributory.

Kawano et al.\(^{(23)}\) assessed the adverse outcomes in 8205 patients taking clopidogrel with or without PPIs after hospitalization for acute coronary syndrome, and reported that patients taking clopidogrel and PPIs showed a significantly increased risk of bleeding. Therefore, PPIs may decrease the level of active metabolite of clopidogrel and attenuate the anti-platelet effect of clopidogrel. Therefore, PPIs may decrease the level of active metabolite of clopidogrel. Therefore, PPIs may decrease the level of active metabolite of clopidogrel. Therefore, PPIs may decrease the level of active metabolite of clopidogrel.
clopidogrel with PPIs had a significantly higher risk of death or rehospitalization for acute coronary syndrome compared with patients taking clopidogrel without PPI.

In conclusion, this study demonstrated that post-ESD ulcers of any size are potentially curable with either H2:RA or PPI therapy in Japan, with outcomes being equivalent at approximately 8 weeks. H2:RAs without effects on CYPs might be safer to treat post-ESD than PPIs because of the potential of drug interactions following concomitant administration of PPIs with other drugs.

References

1 Tada M, Murakami A, Karita M, Yanami H, Okita K. Endoscopic resection of early gastric cancer. *Endoscopy* 1993; 25: 445–450.
2 Hirao M, Masuda K, Asanuma T, *et al*. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. *Gastrointest Endosc* 1988; 34: 264–269.
3 Yamaguchi Y, Katsumi N, Tauchi M, *et al*. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. *Aliment Pharmacol Ther* 2005; 21 (Suppl 2): 111–115.
4 Lee SY, Kim JJ, Lee JH, *et al*. Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. *Gastrointest Endosc* 2004; 60: 213–217.
5 Ohkawa M, Hosokawa K, Boku N, Ohtu A, Tajiri H, Yoshida S. New endoscopic treatment for intramucosal gastric tumors using an insulated-tip diathermic knife. *Endoscopy* 2001; 33: 221–226.
6 Ono H, Kondo H, Gotoda T, *et al*. Endoscopic mucosal resection for treatment of early gastric cancer. *Gut* 2001; 48: 225–229.
7 Tunis SR, Sheinheit IA, Schmid CH, Bishop DJ, Ross SD. Lansoprazole compared with histamine-receptor antagonists in healing gastric ulcers: a meta-analysis. *Clin Ther* 1997; 19: 743–757.
8 Haruma K, Kamada T, Kawaguchi H, *et al*. Effect of age and *Helicobacter pylori* infection on gastric acid secretion. *J Gastroenterol Hepatol* 2000; 15: 277–283.
9 Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. *Helicobacter pylori* independent chronological change in gastric acid secretion in the Japanese. *Gut* 1997; 41: 452–458.
10 Yamamoto H, Kawata H, Sunada K, *et al*. Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. *Endoscopy* 2003; 35: 690–694.
11 Oda I, Gotoda T, Hamanaka H, *et al*. Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. *Dig Endosc* 2005; 17: 54–58.
12 Eriksson S, Långström G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflex oesophagitis: a meta-analysis. *Eur J Gastroenterol Hepatol* 1995; 7: 467–475.
13 Kim YG, Jang BI, Kim TN. A matched case-control study of a novel acid-suppressing antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection. *Gut Liver* 2010; 4: 25–30.
14 Kakehashi N, Yahagi N, Fujishiro M, *et al*. The healing process of gastric artificial ulcers after endoscopic submucosal dissection. *Dig Endosc* 2004; 16: 327–331.
15 Fujiiwara S, Morita Y, Toyonaga T, *et al*. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. *J Gastroenterol* 2011 [Epub ahead of print].
16 Kato T, Araki H, Onogi F, *et al*. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection—a randomized controlled study. *J Gastroenterol* 2010; 45: 285–290.
17 Ichikawa T, Ishihara K, Saigenji K, Hotta K. Structural requirements for roxatidine in the stimulant effect of rat gastric mucin synthesis and the participation of nitric oxide in this mechanism. *Br J Pharmacol* 1997; 122: 1230–1236.
18 Saito H, Sugiyama A, Sato T, *et al*. An influence on the human gastric surface mucous gel layer of roxatidine acetate hydrochloride. *Ulcer Res* 2002; 27: 132–134.
19 Isomoto H, Yamaguchi N. Endoscopic submucosal dissection in the era of proton pump inhibitors. *J Clin Biochem Nutr* 2009; 44: 205–211.
20 Uedo N, Takeuchi Y, Yamada T, *et al*. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. *Am J Gastroenterol* 2007; 102: 1610–1616.
21 Takizawa K, Oda I, Gotoda T, *et al*. Routine coagulation of visible vessels may prevent delayed bleeding after endoscopic submucosal dissection—an analysis of risk factors. *Endoscopy* 2008; 40: 179–183.
22 Kawano S, Okada H, Kawahara Y, *et al*. Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. *Digestion* 2011; 84: 46–53.
23 Ho PM, Maddox TM, Wang L, *et al*. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. *JAMA* 2009; 301: 937–944.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| EMR          | endoscopic mucosal resection |
| ERHSE        | Endoscopic Resection with local injection of Hypertonic Saline Epinephrine solution |
| ESD          | endoscopic submucosal dissection |
| H:RA         | H: receptor antagonist |
| IT           | insulated tip |
| PPI          | proton pump inhibitor |